Update on idiopathic inflammatory myopathies

References

• Bohan A, Peter JB. Polymyositis and dermatomyositis (first part). N Engl J Med 1975; 292: 344–347
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second part). N Engl J Med 1975; 292: 403–407
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971–982
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Clinical, immunopathologic and therapeutic considerations of inflammatory myopathies. Clin Neuropharmacol 1992; 15: 327–351
   PubMedGoogle Scholar
• Greenberg SA, Sanoudou D, Haslett JN, Kohane IS, Kunkel LM, Beggs AH, Amato AA. Molecular profiles of inflammatory myopathies. Neurology 2002; 59: 1170–1182
   PubMed Web of Science ®Google Scholar
• Oddis CV, Conte CG, Steen VD, Medsger TA, Jr. Incidence of polymyositis-dermatomyositis: A 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17: 1329–1334
   PubMed Web of Science ®Google Scholar
• Benbassat J, Geffel D, Zlotnick A. Epidemiology of polymyositis-dermatomyositis in Israel, 1960–76. Isr J Med Sci 1980; 16: 197–200
   PubMedGoogle Scholar
• Weitoft T. Occurrence of polymyositis in the country of Galvleborg, Sweden. Scand J Rheumatol 1997; 26: 104–106
   PubMed Web of Science ®Google Scholar
• Koh ET, Seow A, Ong B, Ratnagopal P, Tija H, Chang HH. Adult onset polymyositis/dermatomyositis: Clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993; 52: 857–861
   PubMed Web of Science ®Google Scholar
• O'Hanlon, Carrick DM, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Dreyfuss J, Shamim EA, Rider LG, Chanock SJ, Foster CB, Bunch T, Plotz PH, Love LA, Miller FW. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine 2005; 84: 338–349
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998; 55: 1509–1512
   PubMed Web of Science ®Google Scholar
• Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: Effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005; 128: 1887–1896
   PubMed Web of Science ®Google Scholar
• Chevrel G, Page G, Miossec P. Novel aspects on the contribution of T cells and dendritic cells in the pathogenesis of myositis. Autoimmunity, in press
   Google Scholar
• Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity, in press
   Google Scholar
• Daniels L, Worthingham C. Muscle testing: Techniques of manual examination3rd ed. W.B. Saunders, Philadelphia 1972; 2–3
   Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993–2000
   PubMed Web of Science ®Google Scholar
• Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, Zemel LS, Wallace CA, Ballinger SH, Passo MH, Reed AM, Summers RM, White PH, Katona IM, Miller FW, Lachenbruch PA, Rider LG. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50: 1595–1603, Juvenile Dermatomyositis Disease Activity Collaborative Study Group
   PubMed Web of Science ®Google Scholar
• Rockerbie NR, Woo TY, Callen JP, Giustina T. Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 1989; 20: 629–632
   PubMed Web of Science ®Google Scholar
• Itoh J, Akiguchi I, Midorikawa R, Kameyama M. Sarcoid myopathy with typical rash of dermatomyositis. Neurology 1980; 30: 1118–1121
   PubMedGoogle Scholar
• Kagen LJ, Hochman RB, Strog EW. Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatopolymyositis). Arthritis Rheum 1985; 28: 630–636
   PubMedGoogle Scholar
• De Merieux P, Verity MA, Clements RJ, Paulus HE. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis. Arthritis Rheum 1983; 26: 961–968
   PubMedGoogle Scholar
• Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pastruel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998; 25: 1336–1343
   PubMed Web of Science ®Google Scholar
• Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, Tamaki K. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology 2000; 39: 632–636
   PubMed Web of Science ®Google Scholar
• Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-Jo-1 antibodies. Autoimmunity 2005; 38: 73–78
   PubMed Web of Science ®Google Scholar
• Haupt HM, Hutchins GM. The heart and cardiac conducting system in polymyositis–dermatomyositis. Am J Cardiol 1982; 50: 998–1006
   PubMed Web of Science ®Google Scholar
• Stern R, Goodbold JH, Chess Q, Kagen LJ. ECG abnormalities in polymyositis. Arch Intern Med 1984; 44: 2185–2189
   Google Scholar
• Kagen LJ. Myoglobinemia and myoglobinuria in patients with myositis. Arthritis Rheum 1971; 14: 457–464
   PubMed Web of Science ®Google Scholar
• Dyck RF, Katz A, Gordon DA, Johnson M, Shain House Z, Cardella CJ, Bear RA. Glomerulonephritis associated with polymyositis. J Rheumatol 1979; 6: 336–344
   PubMed Web of Science ®Google Scholar
• Kamata K, Kobayashi Y, Shigematsu H, Saito T. Childhood type polymyositis and rapidly progressive glomerulonephritis. Acta Pathol Jpn 1982; 32: 801–806
   PubMedGoogle Scholar
• Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med 1986; 80: 329–332
   PubMed Web of Science ®Google Scholar
• Morton BD, III, Statland BE. Serum enzyme alterations in polymyositis. Am J Clin Pathol 1980; 73: 556–557
   PubMed Web of Science ®Google Scholar
• Montecucco C, Caporali R, Lotziker M. Anticorpi anti-sintetasi: Dall'antigene alla sindrome. Reumatismo 2000; 52: 127–131
   Google Scholar
• Roux S, Seelig HP, Meyer O. Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J Rheumatol 1998; 25: 395–396
   PubMedGoogle Scholar
• Walter P, Blobel G. Signal recognition particle contains a 7SRNA essential for proteins translocation across the endoplasmic reticulum. Nature 1982; 299: 691–698
   PubMed Web of Science ®Google Scholar
• Brouwer R, Hengstman GJ, Vree Egberts W, Elurfeld A, Bozic B, Ghirardello A, Grondal G, Hiertarinta M, Isenberg D, Kalden JR, Lundberg I, Moutsopoulos H, Roux-Lombard P, Venckovsky J, Wikman A, Seelig HP, van Engelen BJ, van Venrooij WJ. Autoantibodies profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60: 116–123
   PubMed Web of Science ®Google Scholar
• Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA, Jr. Serum autoantibodies to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 1992; 35: 1211–1217
   PubMed Web of Science ®Google Scholar
• Franceschini F, Cavazzana I, Generali O, Quinzanini M, Viardi L, Ghirardello A, Doria A, Cattaneo R. Anti-ku antibodies in connective tissue diseases: Clinical and serological evaluation of 14 patients. J Rheumatol 2002; 29: 1393–1397
   PubMed Web of Science ®Google Scholar
• Klein-Gunnewiek J, van Aarsen Y, van der Kemp A, Nelissen R, Pruijn GJ, van Venrooij WJ. The U1 snRNP complex: An autoantigen in connective tissue diseases. An update. Clin Exp Rheumatol 1997; 15: 549–560
   PubMedGoogle Scholar
• Askanas V, Engel WK. Proposed pathogenetic cascade of inclusion body myositis: Importance of amyloid-beta, misfolded proteins, predisposing genes and aging. Curr Opin Rheumatol 2003; 15: 737–744
   PubMedGoogle Scholar
• Park JH, Olsen NJ. Skeletal muscle imaging for the evaluation of myopathies. Disease of skeletal muscles, RL Wortmann. Lippincot Williams and Wilkins, Philadelphia 2000; 293–312
   Google Scholar
• Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep 2001; 3: 334–345
   PubMedGoogle Scholar
• Park JH, Vansant JP, Kumar NG, Gibbs SJ, Curvin MS, Price RR, Partain CL, James AE, Jr. Dermatomyositis correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease. Radiology 1990; 177: 473–479
   PubMedGoogle Scholar
• Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991; 18: 1693–1699
   PubMed Web of Science ®Google Scholar
• Reimers CD, Finkenstaedt M. Muscle imaging in inflammatory myopathies. Curr Opin Rheumatol 1997; 9: 475–485
   PubMedGoogle Scholar
• Sekul EA, Chow X, Dalakas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 1997; 48: 863–866
   PubMedGoogle Scholar
• Park JH, Niermann KY, Ryder NM, Nelson AF, Das A, Lawton AR, Hernanz-Schulman M, Olsen NJ. Muscle abnormalities in juvenile dermatomyositis patients: P-31 magnetic resonance spectroscopy studies. Arthritis Rheum 2000; 43(10)2359–2367
   PubMedGoogle Scholar
• Reimers CD, Fleckenstein JL, Witt TN, Müller-Felber W, Pongratz DE. Muscular ultrasound in idiopathic inflammatory myopathies af adults. J Neurol Sci 1993; 116: 82–92
   PubMed Web of Science ®Google Scholar
• Weber MA, Krix M, Jappe U, Huttner HB, Hartmann M, Meyding-Lamade U, Essig M, Fiehn C, Kauczor HU, Delorme S, et al. Pathologic skeletal muscle perfusion in patients with myositis: Detection with quantitative contrast-enhanced US-initial results. Radiology 2006; 238: 640–649, Epub 21 December 2005
   PubMedGoogle Scholar
• Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, Garay S, Kuis W, Machado C, Pachman L, Prieur AM, Rider LG, Silverman F, Tsitsami E, Woo P, Giannini EH, Martini A. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003; 42: 1452–1459, Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG)
   PubMedGoogle Scholar
• Ravelli A, Ruperto N, Trail L, Felici E, Sala E, Martini A. Clinical assessment in juvenile dermatomyositis. Autoimmunity, in press
   Google Scholar
• Callen JP. Dermatomyositis. Lancet 2000; 355: 53–57
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis and polymyositis. A population based study. N Engl J Med 1992; 326: 363–367
   PubMed Web of Science ®Google Scholar
• Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: A population based study. Lancet 2001; 357: 96–100
   PubMed Web of Science ®Google Scholar
• Pautas E, Cherin P, Piette JC, Pelletier S, Wechsler B, Cabane J, Herson S. Features of polymyositis and dermatomyositis in the elderly: A case control study. Clin Exp Rheumatol 2000; 18: 241–244
   PubMed Web of Science ®Google Scholar
• Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A, Gergely L, Danko K. Cancer-associated myositis: Clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051: 64–71
   PubMed Web of Science ®Google Scholar
• Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients. Medicine 2005; 84: 231–249
   PubMed Web of Science ®Google Scholar
• Cumming WJK, Weiser R, Teoh R, Hudgson P, Walton JN. Localized nodular myositis: A clinical and pathological variant of polymyositis. Q J Med 1977; 46: 531
   PubMedGoogle Scholar
• Heffner RR, Jr, Barron SA. Polymyositis beginning as a focal process. Arch Neurol 1981; 38: 439
   PubMedGoogle Scholar
• Lederman RJ, Salanga VD, Wilbourn AJ, Hanson MR, Dudley AW. Focal inflammatory myopathy. Muscle Nerve 1984; 7: 142
   PubMedGoogle Scholar
• Sladek GD, Vasey FB, Sieger B, Behnke DA, Germain BF, Espinoza LR. Relapsing eosinophilic myositis. J Rheumatol 1983; 10: 467–470
   PubMed Web of Science ®Google Scholar
• Watts RA. Eosinophilia and musculoskeletal disease. Curr Opin Rheumatol 2001; 13: 57–61
   PubMedGoogle Scholar
• Hewlett RH, Brownell B. Granulomatous myopathy: Its relationship to sarcoidosis and polymyositis. J Neurol Neurosurg Psychiatry 1975; 38: 1090–1099
   PubMedGoogle Scholar
• Menard DB, Haddad H, Blain JG, Beaudry R, Devroede G, Masi ES. Granulomatosus myositis and myopathy associated with Crohn's colitis. N Engl J Med 1976; 295: 818–819
   PubMed Web of Science ®Google Scholar
• Nirmalananthan N, Holton JL, Hanna MG. Is it really myositis? A consideration of the differential diagnosis. Curr Opin Rheum 2004; 16: 684–691
   PubMedGoogle Scholar
• Choy E, Hoogendijk J, Lecky B, Winer J. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005; 20: CD003643
   Google Scholar
• Oddis CV. Therapy for myositis. Curr Opin Rheumatol 1993; 5: 742–748
   PubMedGoogle Scholar
• Villalba L, Adams EM. Update on therapy for refractory dermatomyositis and polymyositis. Curr Opin Rheumatol 1996; 8: 544–551
   PubMedGoogle Scholar
• Matsubara S, Hirai S, Sawa Y. Pulsed intravenous metylprednisolone therapy for inflammatory myopathies: Evaluation of the effect by comparing two consecutive biopsies from the same muscle. J Neuroimmunol 1997; 76: 75–80
   PubMed Web of Science ®Google Scholar
• Malaviya AN, Many A, Schwartz RS. Treatment of dermatomyositis with methotrexate. Lancet 1968; 2: 485–488
   PubMed Web of Science ®Google Scholar
• Choy EH, Isemberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology 2002; 41: 7–13
   PubMed Web of Science ®Google Scholar
• Keen RW, Gumpel JM. Cyclosporin A in adult dermatomyositis (letter). Br J Rheumatol 1993; 32: 439
   PubMedGoogle Scholar
• LuecK CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991; 54: 1007–1008
   PubMedGoogle Scholar
• Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): An alternative therapy for autoimmune inflammatory myopathy. Rheumatology 2005; 44: 386–389
   PubMed Web of Science ®Google Scholar
• Schneider C, Gold R, Schafers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002; 25: 286–288
   PubMed Web of Science ®Google Scholar
• De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999; 9: 239–246
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, van Engelen BG. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: Preliminary observations. Eur Neurol 2003; 50: 10–15
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 2005; 52: 601–607
   PubMed Web of Science ®Google Scholar
• Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005; 11: 264–266
   PubMed Web of Science ®Google Scholar
• Lambotte O, Durbach A, Kotb R, Ferlicot S, Delfraissy JF, Goujard C. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005; 32: 1369–1370
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004; 291: 2367–2375
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993–2000
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 323–327
   PubMed Web of Science ®Google Scholar
• Walter MC. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 2000; 247: 22–28
   PubMed Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, Eymard B. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002; 58: 326
   PubMed Web of Science ®Google Scholar
• Cherin P, Auperin I, Bussel A, Purrat J, Herson S. Plasma-exchange in polymyositis and dermatomyositis: A multicentre study of 57 cases. Clin Exp Rheumatol 1995; 13: 270–271
   PubMed Web of Science ®Google Scholar
• Miller FW, Leitman SF, Cronin ME, Hickis JE, Leff RL, Wesley R. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326: 1380–1384
   PubMed Web of Science ®Google Scholar
• Alexanderson H, Stenstrom CH, Jenner G, Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000; 29: 295–301
   PubMed Web of Science ®Google Scholar